Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects

• Published in: Biomedicine & pharmacotherapy Vol. 157; p. 113998
• Main Authors: Chen, Jun, Cong, Xiufeng
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.01.2023
• Subjects: Cancer immune response; Cancer immunotherapy; Cancer Vaccines - therapeutic use; Humans; Immunity; Immunotherapy - methods; Nanocarriers; Nanomedicine; Nanoparticles; Neoplasms - therapy; Surface-engineered; Tissue Distribution; TAM; Cancer immune response; PS; SPIONs; BBB; PNPs; MRI; LNPs; MHC; Cancer immunotherapy; LPS; AUC; Nanoparticles; MUC1; GBM; DCs; CLRs; aAPCs; t1/2; O/W; iRGD; HSA; SLNs; MDR; Nanocarriers; MnNPs; APCs; Cmax; NSCLC; Vz; Surface-engineered; MMP2; ASOs; CL; NLCs; PAMAM; VLPs; LNEs; PLGA; PEG; PEI; LESS; PDL1; NK
• ISSN: 0753-3322; 1950-6007; 1950-6007
• DOI: 10.1016/j.biopha.2022.113998

Cancer immunotherapy is a therapeutic strategy to inhibit tumor growth and metastasis by intervening in the immune response process. Strategies applied to cancer immunotherapy mainly include blocking immune checkpoints, adoptive transfer of engineered immune cells, cytokine therapy, cancer vaccines,...